| 1.07 0.09 (9.13%) | 07-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 | 1-year : | 1.53 |
| Resists | First : | 1.16 | Second : | 1.3 |
| Pivot price | 1.04  |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 0.99 |
MA(20) : | 1.09 |
| MA(100) : | 1.72 |
MA(250) : | 4.76 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.3 |
D(3) : | 11.5 |
| RSI | RSI(14): 38.6 |
|||
| 52-week | High : | 12.22 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TPST ] has closed below upper band by 41.1%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.1 | 1.1 - 1.1 |
| Low: | 0.98 - 0.99 | 0.99 - 0.99 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Wed, 08 Jul 2026
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
Wed, 08 Jul 2026
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Sat, 27 Jun 2026
TPST Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 26 Jun 2026
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan
Tue, 23 Jun 2026
Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances - Stock Titan
Tue, 23 Jun 2026
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 31.7 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 285 (K) |
| Shares Short P.Month | 341 (K) |
| EPS | -5.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61.7 % |
| Return on Equity (ttm) | -721 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 17.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|